Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00423787 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety/Tolerability of Ragweed MATA MPL
A Phase 3 study, sponsored by Allergy Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 993
- Enrollment target
NCT00423787 is a Phase 3 study that has completed, run by Allergy Therapeutics. The registered enrollment target is 993 participants.
The verdict
NCT00423787, a Phase 3 study, has completed, sponsored by Allergy Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 993 participants
- Enrollment target
Study Summary
Ragweed MATAMPL has been developed by Allergy Therapeutics to provide pre-seasonal specific immunotherapy for patients with proven type I hypersensitivity to cross reacting ragweed pollens causing rhinitis and/or conjunctivitis with or without mild to moderate asthma bronchiale. The purpose of this study is to compare the efficacy of Ragweed MATAMPL versus placebo in ragweed-allergic subjects following 4 subcutaneous injections of study medication administered before the start of the 2007 ragweed pollen season
Interventions
- BIOLOGICAL Ragweed MATA MPL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 993 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00423787
The ClinicalTrials.gov registry entry for NCT00423787 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 993 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergy Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ragweed MATA MPL is the first listed.
NCT00423787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00423787 about?
NCT00423787 is a clinical study titled "Efficacy and Safety/Tolerability of Ragweed MATA MPL". Ragweed MATAMPL has been developed by Allergy Therapeutics to provide pre-seasonal specific immunotherapy for patients with proven type I hypersensitivity to cross reacting ragweed pollens causing rhinitis and/or conjunctivitis with or without mild to moderate asthma bronchiale. The purpose of this ...
What is the current status of trial NCT00423787?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 993 participants. The study started on 2007-03. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00423787?
The interventions under investigation include: Ragweed MATA MPL (BIOLOGICAL).
Who is sponsoring clinical trial NCT00423787?
This trial is sponsored by Allergy Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.